Women’s Health Diagnostics Market by Application (Biopsy, Cervical & Ovarian Cancer Testing, PAP Smear, HPV, TORCH, Prenatal Testing, Hepatitis, Ultrasound, Obstetrics), End User (Hospitals, Clinics, Home Care), COVID-19 Impact – Global Forecast to 2025

世界の女性向け健康診断市場予測:用途別、エンドユーザー別

◆タイトル:Women’s Health Diagnostics Market by Application (Biopsy, Cervical & Ovarian Cancer Testing, PAP Smear, HPV, TORCH, Prenatal Testing, Hepatitis, Ultrasound, Obstetrics), End User (Hospitals, Clinics, Home Care), COVID-19 Impact – Global Forecast to 2025
◆商品コード:MD4774
◆調査・発行会社:MarketsandMarkets
◆発行日:2021年2月20日
◆ページ数:238
◆レポート形式:PDF / 英語
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧)USD4,950 ⇒換算¥544,500見積依頼/購入/質問フォーム
Multi User (Five User)USD6,650 ⇒換算¥731,500見積依頼/購入/質問フォーム
Corporate License (全社内共有可)USD8,150 ⇒換算¥896,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※商品の納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※ご購入後、レポートに記載の英語表現や単語の意味に関しましては無料でお答えいたします。(但し、対応範囲は弊社で判断)
※弊社H&Iグローバルリサーチ株式会社はMarketsandMarketsの日本における正規販売代理店です。

【レポートの概要】

マーケッツアンドマーケッツ社は世界の女性向け健康診断市場規模が2020年250億ドルから2025年366億ドルまで、年平均7.9%成長すると予想しています。本調査レポートでは、女性向け健康診断の世界市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、プレミアムインサイト、市場概要、用途別(乳がん検査、感染症検査、HPV検査、STD検査、骨粗鬆症検査、その他)分析、エンドユーザー別(病院・診療所、診断・画像センター、在宅医療)分析、地域別分析、競争状況、企業情報などをまとめております。
・イントロダクション
・調査手法
・エグゼクティブサマリー
・プレミアムインサイト
・市場概要
・世界の女性向け健康診断市場規模:用途別(乳がん検査、感染症検査、HPV検査、STD検査、骨粗鬆症検査、その他)
・世界の女性向け健康診断市場規模:エンドユーザー別(病院・診療所、診断・画像センター、在宅医療)
・世界の女性向け健康診断市場規模:地域別
・競争状況
・企業情報

“The women’s health diagnostics market is projected to reach USD 36.6 billion by 2025 from USD 25.0 billion in 2020, at a CAGR of 7.9% during the forecast period.”
In the past decade, the demand for various health diagnostic tests has increased significantly across the globe. Currently, the market is mainly driven by growing awareness about various health-related disorders, rising incidence of chronic and lifestyle disorders, and the high prevalence of infectious diseases such as HIV and hepatitis in women across the globe. The increasing adoption of POC diagnostic testing and the growth in the number of diagnostic and imaging centers are also expected to support the growth of this market during the forecast period. However, the high cost of diagnostic devices, tests, and procedures; shortage of skilled laboratory technicians; and insufficient reimbursements for diagnostic tests are expected to restrain this market’s growth to a certain extent.

“Based on application, the breast cancer testing segment holds the largest market share during the forecast period.”
Based on application, the women’s health diagnostics market is divided into nine segments—osteoporosis testing, OVC testing, cervical cancer testing, breast cancer testing, pregnancy & fertility testing, prenatal genetic screening & carrier testing, infectious disease testing, STD testing, and ultrasound tests. The breast cancer testing segment accounted for the larger market share in 2019. The large share of this segment can be attributed to the increasing incidence of breast cancer and rising awareness about advanced breast cancer diagnostic techniques, such as ABUS.

“Based on end user, the home care settings segment is expected to register the highest CAGR during the forecast period.”
Based on end users, the women’s health diagnostics market is segmented into hospitals & clinics, diagnostic & imaging centers, and home care settings. The home care settings segment is expected to witness the highest growth during the forecast period. The increasing advantages of using self-testing kits will continue to drive market growth. Patient self-testing enables patients to better manage their diseases by utilizing home/self-testing kits. Technological advancements have made many self-testing kits available for various conditions, such as pregnancy and ovulation.

“North America is expected to account for the largest share of the women’s health diagnostics market in 2019”
In 2019, North America accounted for the largest share of the women’s health diagnostics market, followed by Europe, the Asia Pacific, Latin America, and the Middle East & Africa. The large share of this market segment can be attributed to the increasing prevalence of cancer among women, the growing focus of manufacturers of women’s health diagnostic products on expanding their presence in this region, and the increasing demand for fertility testing monitors. In addition, the rising acceptance of POC diagnostics and PST practices is also expected to drive the growth of this regional segment during the forecast period.

Break of primary participants was as mentioned below:
• By Company Type – Tier 1–35%, Tier 2–45%, and Tier 3–20%
• By Designation – C-level–35%, Director-level–25%, Others–40%
• By Region – North America–45%, Europe–30%, Asia Pacific–20%, Latin America- 3%, Middle East and Africa–2%

Key players in the Inspection Machines market
The key players operating in the women’s health diagnostics market include Quest Diagnostics Incorporated (US), Hologic, Inc. (US), Siemens AG (Germany), PerkinElmer, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Cardinal Health, Inc. (US), General Electric Company (US), Becton, Dickinson and Company (US), Abbott Laboratories (US), bioMérieux SA (France), Koninklijke Philips N.V. (Netherlands), Guided Therapeutics, Inc. (US), SuperSonic Imagine (France), FUJIFILM Holdings Corporation (Japan), DIALAB GmbH (Austria), Carestream Health, Inc. (US), MedGyn Products, Inc. (US), Cook Medical, Inc. (US), Osteometer MediTech, Inc. (Denmark), and NeuroLogica Corporation (US).

Research Coverage:
The report analyzes the women’s health diagnostics market and aims at estimating the market size and future growth potential of this market based on various segments such as application type, end user, and region. The report also includes a product portfolio matrix of various women’s health diagnostic products available in the market. The report also provides a competitive analysis of the key players in this market, along with their company profiles, product offerings, and key market strategies.

Reasons to Buy the Report
The report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn would help them, garner a more significant share of the market. Firms purchasing the report could use one or any combination of the below-mentioned strategies to strengthen their position in the market.

This report provides insights into the following pointers:
• Market Penetration: Comprehensive information on product portfolios offered by the top players in the global women’s health diagnostics market. The report analyzes this market by application, and end user
• Product Enhancement/Innovation: Detailed insights on upcoming trends and product launches in the global women’s health diagnostics market
• Market Development: Comprehensive information on the lucrative emerging markets by application, and end user
• Market Diversification: Exhaustive information about new products or product enhancements, growing geographies, recent developments, and investments in the global women’s health diagnostics market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, competitive leadership mapping, and capabilities of leading players in the global women’s health diagnostics market.

【レポートの目次】

1 INTRODUCTION 32
1.1 OBJECTIVES OF THE STUDY 32
1.2 MARKET DEFINITION & SCOPE 33
1.2.1 INCLUSIONS AND EXCLUSIONS 33
1.2.2 MARKETS COVERED 33
FIGURE 1 WOMEN’S HEALTH DIAGNOSTICS MARKET 33
1.2.3 YEARS CONSIDERED FOR THE STUDY 34
1.3 CURRENCY 34
1.4 STAKEHOLDERS 34
1.5 LIMITATIONS 35
1.6 SUMMARY OF CHANGES 35
2 RESEARCH METHODOLOGY 36
2.1 RESEARCH APPROACH 36
FIGURE 2 RESEARCH DESIGN 36
2.1.1 SECONDARY RESEARCH 36
2.1.1.1 Key data from secondary sources 37
2.1.2 PRIMARY RESEARCH 38
FIGURE 3 PRIMARY SOURCES 38
2.1.2.1 Key data from primary sources 39
2.1.2.2 Breakdown of primaries 39
FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 39
2.2 MARKET SIZE ESTIMATION 40
FIGURE 5 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 40
FIGURE 6 REVENUE SHARE ANALYSIS ILLUSTRATION 41
FIGURE 7 MARKET ANALYSIS APPROACH 41
FIGURE 8 TOP-DOWN APPROACH 42
2.3 DATA TRIANGULATION APPROACH 44
FIGURE 9 DATA TRIANGULATION METHODOLOGY 44
2.4 MARKET SHARE ESTIMATION 45
2.5 ASSUMPTIONS FOR THE STUDY 45
3 EXECUTIVE SUMMARY 46
FIGURE 10 WOMEN’S HEALTH DIAGNOSTICS MARKET, BY APPLICATION, 2020 VS. 2025 46
FIGURE 11 WOMEN’S HEALTH DIAGNOSTICS MARKET, BY END USER, 2020 VS. 2025 47
FIGURE 12 GEOGRAPHIC SNAPSHOT: WOMEN’S HEALTH DIAGNOSTICS MARKET 47

4 PREMIUM INSIGHTS 49
4.1 WOMEN’S HEALTH DIAGNOSTICS MARKET OVERVIEW 49
FIGURE 13 RISING INCIDENCE OF CHRONIC AND LIFESTYLE-RELATED DISORDERS TO DRIVE GROWTH IN THE WOMEN’S HEALTH DIAGNOSTICS MARKET 49
4.2 APAC: PREGNANCY & FERTILITY TESTING MARKET, BY TYPE (2019) 50
FIGURE 14 PREGNANCY TESTING & OVULATION PREDICTION KITS DOMINATED THE APAC PREGNANCY & FERTILITY TESTING MARKET IN 2019 50
4.3 GEOGRAPHIC SNAPSHOT OF THE WOMEN’S HEALTH DIAGNOSTICS MARKET 51
FIGURE 15 THE US COMMANDED THE LARGEST SHARE OF THE WOMEN’S HEALTH DIAGNOSTICS MARKET IN 2019 51
4.4 GEOGRAPHIC MIX: WOMEN’S HEALTH DIAGNOSTICS MARKET 52
FIGURE 16 APAC TO WITNESS THE HIGHEST CAGR DURING THE FORECAST PERIOD 52
5 MARKET OVERVIEW 53
5.1 INTRODUCTION 53
5.2 MARKET DYNAMICS 53
TABLE 1 WOMEN’S HEALTH DIAGNOSTICS MARKET: IMPACT ANALYSIS 53
5.2.1 MARKET DRIVERS 54
5.2.1.1 High prevalence of infectious diseases in women 54
5.2.1.2 Rising incidence of chronic and lifestyle-related disorders in women 54
5.2.1.3 Increasing awareness about fertility testing in women and initiatives by government and health organizations 55
5.2.1.4 Increased adoption of POC and rapid diagnostic tests 56
5.2.1.5 Growth in the number of private diagnostic and imaging centers 56
5.2.1.6 Public-private partnerships are expected to enhance infrastructure in diagnostic imaging centers 57
5.2.2 MARKET RESTRAINTS 57
5.2.2.1 High cost of diagnostic imaging systems and procedures 57
5.2.2.2 Shortage of skilled laboratory technicians 57
5.2.3 MARKET OPPORTUNITIES 58
5.2.3.1 Improving healthcare infrastructure in emerging markets 58
5.2.3.2 Growing number of regulatory approvals for immunoassay diagnostic techniques 59
5.2.4 MARKET CHALLENGES 59
5.2.4.1 Stringent regulatory guidelines 59
5.2.4.2 Increasing adoption of refurbished diagnostic imaging systems 60
5.3 COVID-19 IMPACT ON THE WOMEN’S HEALTH DIAGNOSTICS MARKET 60
6 WOMEN’S HEALTH DIAGNOSTICS MARKET, BY APPLICATION 62
6.1 INTRODUCTION 63
TABLE 2 WOMEN’S HEALTH DIAGNOSTICS MARKET: PRODUCT PORTFOLIO ANALYSIS 63
TABLE 3 WOMEN’S HEALTH DIAGNOSTICS MARKET, BY APPLICATION, 2018–2025 (USD MILLION) 64

6.2 BREAST CANCER TESTING 64
TABLE 4 BREAST CANCER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 65
TABLE 5 BREAST CANCER TESTING MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 65
6.2.1 MAMMOGRAPHY 66
6.2.1.1 Rising awareness of early detection of breast cancer to fuel the market growth 66
TABLE 6 MAMMOGRAPHY MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 66
6.2.2 BREAST CANCER TUMOR MARKER TESTS 67
6.2.2.1 Increasing number of newly diagnosed breast cancer cases will drive the demand for breast cancer tumor marker tests 67
TABLE 7 BREAST CANCER TUMOR MARKER TESTS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 67
6.2.3 BLOOD CHEMISTRY & BLOOD CELL COUNT TESTS 68
6.2.3.1 Growing need for checking the proper functioning of body organs and preventing the spread of infection to other organs will drive market growth 68
TABLE 8 BLOOD CHEMISTRY & BLOOD CELL COUNT TESTS MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 68
6.2.4 BIOPSIES 69
6.2.4.1 Growing incidence of breast cancer and high demand for minimally invasive procedures to augment market growth 69
TABLE 9 BIOPSIES MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 69
6.2.5 OTHER BREAST CANCER TESTS 69
TABLE 10 OTHER BREAST CANCER TESTS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 70
6.3 INFECTIOUS DISEASE TESTING 70
TABLE 11 INFECTIOUS DISEASE TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 71
TABLE 12 INFECTIOUS DISEASE TESTING MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 71
6.3.1 UTI TESTING 72
6.3.1.1 Technological advancements like CT scans and ultrasound increase the need for UTI testing 72
TABLE 13 UTI TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 72
6.3.2 HEPATITIS TESTING 73
6.3.2.1 Dynamic shift from traditional diagnostic procedures to portable tests is expected to propel market growth 73
TABLE 14 HEPATITIS TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 74
6.3.3 TUBERCULOSIS TESTING 74
6.3.3.1 Rising tuberculosis cases in women will drive the demand for infectious disease testing 74
TABLE 15 TUBERCULOSIS TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 75
6.3.4 MRSA TESTING 75
6.3.4.1 Development of rapid MRSA tests will drive the market growth 75
TABLE 16 MRSA TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 76
6.3.5 OTHER INFECTIOUS DISEASE TESTS 76
TABLE 17 OTHER INFECTIOUS DISEASE TESTS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 77
6.4 CERVICAL CANCER TESTING 77
TABLE 18 CERVICAL CANCER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 78
TABLE 19 CERVICAL CANCER TESTING MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 78
6.4.1 HPV TESTING 78
6.4.1.1 Easy availability of advanced tests and growing demand for using Pap/HPV co-testing to support market growth 78
TABLE 20 HPV TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 79
6.4.2 PAP SMEARS 79
6.4.2.1 Rising cervical cancer cases and government initiatives are propelling the growth of the market 79
TABLE 21 PAP SMEARS MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 80
6.5 STD TESTING 80
TABLE 22 STD TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 81
TABLE 23 STD TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 81
6.5.1 HIV TESTING 82
6.5.1.1 Increasing government support and technological advancements are major factors driving market growth 82
TABLE 24 HIV TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 83
6.5.2 CT/NG TESTING 83
6.5.2.1 Technological advancements and rapid testing to drive market growth in this application segment 83
TABLE 25 CT/NG TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 84
6.5.3 OTHER STD TESTS 84
TABLE 26 OTHER STD TESTS MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 85
6.6 OSTEOPOROSIS TESTING 85
TABLE 27 OSTEOPOROSIS TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 86
TABLE 28 OSTEOPOROSIS TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 86
6.6.1 IN VITRO BLOOD TESTS 86
6.6.1.1 Growing risk of osteoporosis in women during menopause to drive the demand for in vitro blood tests 86
TABLE 29 IN VITRO BLOOD TESTS MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 87
6.6.2 BONE DENSITOMETRY 87
6.6.2.1 Growing aging population and high prevalence of osteoporosis in woman to drive the demand for this application segment 87
TABLE 30 BONE DENSITOMETRY MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 88
6.7 PRENATAL GENETIC SCREENING & CARRIER TESTING 88
TABLE 31 PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 89
TABLE 32 PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 89
6.7.1 DOWN’S SYNDROME AND EDWARDS’ SYNDROME TESTING 90
6.7.1.1 Rising need for prenatal screening and easy availability of these tests to support market demand 90
TABLE 33 DOWN’S SYNDROME AND EDWARDS’ SYNDROME TESTING MARKET,
BY COUNTRY, 2018–2025 (USD MILLION) 90
6.7.2 TORCH TESTING 91
6.7.2.1 Various advantages of TORCH testing to drive the market demand 91
TABLE 34 TORCH TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 91
6.7.3 CF TESTING 91
6.7.3.1 Growing awareness about genetic disorders like cystic fibrosis to increase the demand for CF testing 91
TABLE 35 CF TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 92
6.7.4 OTHER PRENATAL GENETIC DISEASE TESTS 92
TABLE 36 OTHER PRENATAL GENETIC DISEASE TESTS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 93
6.8 PREGNANCY & FERTILITY TESTING 93
TABLE 37 PREGNANCY & FERTILITY TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 94
TABLE 38 PREGNANCY & FERTILITY TESTING MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 94
6.8.1 PREGNANCY TESTING & OVULATION PREDICTION KITS 95
6.8.1.1 Growing preference for confidentiality and accessibility of test results will drive market demand 95
TABLE 39 PREGNANCY TESTING & OVULATION PREDICTION KITS MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 95
6.8.2 LAB-BASED TESTING 96
6.8.2.1 Increasing reliability of lab-based fertility tests to fuel market growth 96
TABLE 40 LAB-BASED TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 96
6.8.3 FERTILITY MONITORS 97
6.8.3.1 Fast and accurate data generation to increase the demand for fertility monitors 97
TABLE 41 FERTILITY MONITORS MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 97
6.9 ULTRASOUND TESTS 98
TABLE 42 ULTRASOUND TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 98
TABLE 43 ULTRASOUND TESTS MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 98
6.9.1 OB/GYN IMAGING 99
6.9.1.1 Growing demand for minimally invasive techniques in gynecological applications to support market growth 99
TABLE 44 OB/GYN IMAGING MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 99
6.9.2 BREAST IMAGING 100
6.9.2.1 Growing cases of breast cancer and the need for non-invasive procedures will drive the market demand for breast imaging 100
TABLE 45 BREAST IMAGING MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 100
6.10 OVC TESTING 101
TABLE 46 OVC TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 101
TABLE 47 OVC TESTING MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 102
6.10.1 OVC TUMOR MARKER TESTS 102
6.10.1.1 Need for early diagnosis of OVC will drive the demand for advanced diagnostic devices 102
TABLE 48 OVC TUMOR MARKER TESTS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 103
6.10.2 OVC DIAGNOSTIC IMAGING TESTS 103
6.10.2.1 Rising prevalence of women’s health-related disorders and growing awareness about various imaging tests to drive market growth 103
TABLE 49 OVC DIAGNOSTIC IMAGING TESTS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 104
6.10.3 OTHER OVC TESTS 104
TABLE 50 OTHER OVC TESTS MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 105
7 WOMEN’S HEALTH DIAGNOSTICS MARKET, BY END USER 106
7.1 INTRODUCTION 107
7.2 COVID-19 IMPACT ON THE WOMEN’S HEALTH DIAGNOSTICS MARKET, BY END USER 107
TABLE 51 WOMEN’S HEALTH DIAGNOSTICS MARKET, BY END USER,
2018–2025 (USD MILLION) 107
7.3 HOSPITALS & CLINICS 108
7.3.1 HOSPITALS & CLINICS ARE EXPECTED TO DOMINATE THE GLOBAL MARKET DURING THE FORECAST PERIOD 108
TABLE 52 WOMEN’S HEALTH DIAGNOSTICS MARKET FOR HOSPITALS & CLINICS,
BY COUNTRY, 2018–2025 (USD MILLION) 108
7.4 DIAGNOSTIC & IMAGING CENTERS 109
7.4.1 INCREASING NUMBER OF PRIVATE IMAGING CENTERS TO
DRIVE MARKET GROWTH 109
TABLE 53 WOMEN’S HEALTH DIAGNOSTICS MARKET FOR DIAGNOSTIC & IMAGING CENTERS, BY COUNTRY, 2018–2025 (USD MILLION) 109
7.5 HOME CARE SETTINGS 110
7.5.1 INCREASING ADVANTAGES OF USING SELF-TESTING KITS TO DRIVE GROWTH IN THE MARKET 110
TABLE 54 WOMEN’S HEALTH DIAGNOSTICS MARKET FOR HOME CARE SETTINGS,
BY COUNTRY, 2018–2025 (USD MILLION) 110
8 WOMEN’S HEALTH DIAGNOSTICS MARKET, BY REGION 111
8.1 INTRODUCTION 112
8.2 COVID-19 IMPACT ON VARIOUS REGIONS IN THE WOMEN’S HEALTH DIAGNOSTICS MARKET 112
FIGURE 17 WOMEN’S HEALTH DIAGNOSTICS MARKET: GEOGRAPHIC SNAPSHOT (2019) 113
TABLE 55 WOMEN’S HEALTH DIAGNOSTICS MARKET, BY REGION, 2018–2025 (USD MILLION) 113
8.3 NORTH AMERICA 114
FIGURE 18 NORTH AMERICA: WOMEN’S HEALTH DIAGNOSTICS MARKET SNAPSHOT 115
TABLE 56 NORTH AMERICA: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY COUNTRY, 2018–2025 (USD MILLION) 115
TABLE 57 NORTH AMERICA: WOMEN’S HEALTH DIAGNOSTICS MARKET,
BY APPLICATION, 2018–2025 (USD MILLION) 116
TABLE 58 NORTH AMERICA: BREAST CANCER TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 116
TABLE 59 NORTH AMERICA: OSTEOPOROSIS TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 117
TABLE 60 NORTH AMERICA: INFECTIOUS DISEASE TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 117
TABLE 61 NORTH AMERICA: PREGNANCY & FERTILITY TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 117
TABLE 62 NORTH AMERICA: ULTRASOUND TESTS MARKET, BY TYPE,
2018–2025 (USD MILLION) 118
TABLE 63 NORTH AMERICA: STD TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 118
TABLE 64 NORTH AMERICA: PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 118
TABLE 65 NORTH AMERICA: CERVICAL CANCER TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 119
TABLE 66 NORTH AMERICA: OVC TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 119
TABLE 67 NORTH AMERICA: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION) 119
8.3.1 US 120
8.3.1.1 The US dominates the North American women’s health diagnostics market 120
TABLE 68 US: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 120
TABLE 69 US: BREAST CANCER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 121
TABLE 70 US: OSTEOPOROSIS TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 121
TABLE 71 US: INFECTIOUS DISEASE TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 121
TABLE 72 US: PREGNANCY & FERTILITY TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 122
TABLE 73 US: ULTRASOUND TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 122
TABLE 74 US: STD TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 122
TABLE 75 US: PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 123
TABLE 76 US: CERVICAL CANCER TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 123
TABLE 77 US: OVC TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 123
TABLE 78 US: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY END USER,
2018–2025 (USD MILLION) 124
8.3.2 CANADA 124
8.3.2.1 Surge in chronic lifestyle diseases and infectious diseases to support market growth in Canada 124
TABLE 79 CANADA: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY APPLICATION, 2018–2025 (USD MILLION) 124
TABLE 80 CANADA: BREAST CANCER TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 125
TABLE 81 CANADA: OSTEOPOROSIS TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 125
TABLE 82 CANADA: INFECTIOUS DISEASE TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 125
TABLE 83 CANADA: PREGNANCY & FERTILITY TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 126
TABLE 84 CANADA: ULTRASOUND TESTS MARKET, BY TYPE,
2018–2025 (USD MILLION) 126
TABLE 85 CANADA: STD TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 126
TABLE 86 CANADA: PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET,
BY TYPE, 2018–2025 (USD MILLION) 127
TABLE 87 CANADA: CERVICAL CANCER TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 127
TABLE 88 CANADA: OVC TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 127
TABLE 89 CANADA: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY END USER,
2018–2025 (USD MILLION) 128

8.4 EUROPE 128
TABLE 90 EUROPE: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 129
TABLE 91 EUROPE: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY APPLICATION, 2018–2025 (USD MILLION) 129
TABLE 92 EUROPE: BREAST CANCER TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 130
TABLE 93 EUROPE: OSTEOPOROSIS TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 130
TABLE 94 EUROPE: INFECTIOUS DISEASE TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 130
TABLE 95 EUROPE: PREGNANCY & FERTILITY TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 131
TABLE 96 EUROPE: ULTRASOUND TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 131
TABLE 97 EUROPE: STD TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 131
TABLE 98 EUROPE: PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET,
BY TYPE, 2018–2025 (USD MILLION) 132
TABLE 99 EUROPE: CERVICAL CANCER TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 132
TABLE 100 EUROPE: OVC TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 132
TABLE 101 EUROPE: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY END USER,
2018–2025 (USD MILLION) 133
8.4.1 GERMANY 133
8.4.1.1 Growing investments by government and private contributors to fuel market growth 133
TABLE 102 GERMANY: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY APPLICATION, 2018–2025 (USD MILLION) 134
TABLE 103 GERMANY: BREAST CANCER TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 134
TABLE 104 GERMANY: OSTEOPOROSIS TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 134
TABLE 105 GERMANY: INFECTIOUS DISEASE TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 135
TABLE 106 GERMANY: PREGNANCY & FERTILITY TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 135
TABLE 107 GERMANY: ULTRASOUND TESTS MARKET, BY TYPE,
2018–2025 (USD MILLION) 135
TABLE 108 GERMANY: STD TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 136
TABLE 109 GERMANY: PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET,
BY TYPE, 2018–2025 (USD MILLION) 136
TABLE 110 GERMANY: CERVICAL CANCER TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 136
TABLE 111 GERMANY: OVC TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 137
TABLE 112 GERMANY: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY END USER,
2018–2025 (USD MILLION) 137
8.4.2 UK 137
8.4.2.1 Rising incidence of PCOS to increase the demand for diagnostic tests 137
TABLE 113 UK: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY APPLICATION, 2018–2025 (USD MILLION) 138
TABLE 114 UK: BREAST CANCER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 138
TABLE 115 UK: OSTEOPOROSIS TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 138
TABLE 116 UK: INFECTIOUS DISEASE TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 139
TABLE 117 UK: PREGNANCY & FERTILITY TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 139
TABLE 118 UK: ULTRASOUND TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 139
TABLE 119 UK: STD TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 140
TABLE 120 UK: PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 140
TABLE 121 UK: CERVICAL CANCER TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 140
TABLE 122 UK: OVC TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 141
TABLE 123 UK: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY END USER,
2018–2025 (USD MILLION) 141
8.4.3 FRANCE 141
8.4.3.1 Growing infertility rate among women in the country and rising cancer cases to drive the market 141
TABLE 124 FRANCE: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 142
TABLE 125 FRANCE: BREAST CANCER TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 142
TABLE 126 FRANCE: OSTEOPOROSIS TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 142
TABLE 127 FRANCE: INFECTIOUS DISEASE TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 143
TABLE 128 FRANCE: PREGNANCY & FERTILITY TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 143
TABLE 129 FRANCE: ULTRASOUND TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 143
TABLE 130 FRANCE: STD TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 144
TABLE 131 FRANCE: PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET,
BY TYPE, 2018–2025 (USD MILLION) 144
TABLE 132 FRANCE: CERVICAL CANCER TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 144
TABLE 133 FRANCE: OVC TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 145
TABLE 134 FRANCE: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY END USER,
2018–2025 (USD MILLION) 145
8.4.4 ITALY 145
8.4.4.1 Increasing acceptance of molecular diagnostics-based personalized medicine and rising chronic diseases are major driving factors 145
TABLE 135 ITALY: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 146
TABLE 136 ITALY: BREAST CANCER TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 146
TABLE 137 ITALY: OSTEOPOROSIS TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 146
TABLE 138 ITALY: INFECTIOUS DISEASE TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 147
TABLE 139 ITALY: PREGNANCY & FERTILITY TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 147
TABLE 140 ITALY: ULTRASOUND TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 147
TABLE 141 ITALY: STD TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 148
TABLE 142 ITALY: PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET,
BY TYPE, 2018–2025 (USD MILLION) 148
TABLE 143 ITALY: CERVICAL CANCER TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 148
TABLE 144 ITALY: OVC TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 149
TABLE 145 ITALY: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY END USER,
2018–2025 (USD MILLION) 149
8.4.5 SPAIN 149
8.4.5.1 Improving healthcare system and increasing healthcare expenditure in Spain to drive market growth 149
TABLE 146 SPAIN: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 150
TABLE 147 SPAIN: BREAST CANCER TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 150
TABLE 148 SPAIN: OSTEOPOROSIS TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 150
TABLE 149 SPAIN: INFECTIOUS DISEASE TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 151
TABLE 150 SPAIN: PREGNANCY & FERTILITY TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 151
TABLE 151 SPAIN: ULTRASOUND TESTS MARKET, BY TYPE, 2018–2025, (USD MILLION) 151
TABLE 152 SPAIN: STD TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 152
TABLE 153 SPAIN: PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET,
BY TYPE, 2018–2025 (USD MILLION) 152
TABLE 154 SPAIN: CERVICAL CANCER TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 152
TABLE 155 SPAIN: OVC TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 153
TABLE 156 SPAIN: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY END USER,
2018–2025 (USD MILLION) 153
8.4.6 ROE 153
TABLE 157 ROE: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 154
TABLE 158 ROE: BREAST CANCER TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 154
TABLE 159 ROE: OSTEOPOROSIS TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 154
TABLE 160 ROE: INFECTIOUS DISEASE TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 155
TABLE 161 ROE: PREGNANCY & FERTILITY TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 155
TABLE 162 ROE: ULTRASOUND TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 155
TABLE 163 ROE: STD TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 156
TABLE 164 ROE: PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 156
TABLE 165 ROE: CERVICAL CANCER TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 156
TABLE 166 ROE: OVC TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 157
TABLE 167 ROE: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY END USER,
2018–2025 (USD MILLION) 157
8.5 APAC 157
FIGURE 19 APAC: WOMEN’S HEALTH DIAGNOSTICS MARKET SNAPSHOT 158
TABLE 168 APAC: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY COUNTRY,
2018–2025 (USD MILLION) 159
TABLE 169 APAC: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 159
TABLE 170 APAC: BREAST CANCER TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 160
TABLE 171 APAC: OSTEOPOROSIS TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 160
TABLE 172 APAC: INFECTIOUS DISEASE TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 160
TABLE 173 APAC: PREGNANCY & FERTILITY TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 161
TABLE 174 APAC: ULTRASOUND TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 161
TABLE 175 APAC: STD TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 161
TABLE 176 APAC: PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET,
BY TYPE, 2018–2025 (USD MILLION) 162
TABLE 177 APAC: CERVICAL CANCER TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 162
TABLE 178 APAC: OVC TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 162
TABLE 179 APAC: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY END USER,
2018–2025 (USD MILLION) 163
8.5.1 CHINA 163
8.5.1.1 Increasing urbanization and growing government initiatives to drive market growth in China 163
TABLE 180 CHINA: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 164
TABLE 181 CHINA: BREAST CANCER TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 164
TABLE 182 CHINA: OSTEOPOROSIS TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 164
TABLE 183 CHINA: INFECTIOUS DISEASE TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 165
TABLE 184 CHINA: PREGNANCY & FERTILITY TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 165
TABLE 185 CHINA: ULTRASOUND TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 165
TABLE 186 CHINA: STD TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 166
TABLE 187 CHINA: PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET,
BY TYPE, 2018–2025 (USD MILLION) 166
TABLE 188 CHINA: CERVICAL CANCER TESTING MARKET, BY TYPE,
2018–2025, (USD MILLION) 166
TABLE 189 CHINA: OVC TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 167
TABLE 190 CHINA: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY END USER,
2018–2025 (USD MILLION) 167
8.5.2 JAPAN 167
8.5.2.1 Presence of a universal healthcare reimbursement scenario and well-developed healthcare system to drive market growth in Japan 167
TABLE 191 JAPAN: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 168
TABLE 192 JAPAN: BREAST CANCER TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 168
TABLE 193 JAPAN: OSTEOPOROSIS TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 169
TABLE 194 JAPAN: INFECTIOUS DISEASE TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 169
TABLE 195 JAPAN: PREGNANCY & FERTILITY TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 169
TABLE 196 JAPAN: ULTRASOUND TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 170
TABLE 197 JAPAN: STD TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 170
TABLE 198 JAPAN: PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET,
BY TYPE, 2018–2025 (USD MILLION) 170
TABLE 199 JAPAN: CERVICAL CANCER TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 171
TABLE 200 JAPAN: OVC TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 171
TABLE 201 JAPAN: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY END USER,
2018–2025 (USD MILLION) 171
8.5.3 INDIA 172
8.5.3.1 Improving healthcare infrastructure and growing private and public investments to support the market growth 172
TABLE 202 INDIA: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY APPLICATION,
2018–2025 (USD MILLION) 172
TABLE 203 INDIA: BREAST CANCER TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 173
TABLE 204 INDIA: OSTEOPOROSIS TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 173
TABLE 205 INDIA: INFECTIOUS DISEASE TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 173
TABLE 206 INDIA: PREGNANCY & FERTILITY TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 174
TABLE 207 INDIA: ULTRASOUND TESTS MARKET, BY TYPE, 2018–2025 (USD MILLION) 174
TABLE 208 INDIA: STD TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 174
TABLE 209 INDIA: PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET,
BY TYPE, 2018–2025 (USD MILLION) 175
TABLE 210 INDIA: CERVICAL CANCER TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 175
TABLE 211 INDIA: OVC TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 175
TABLE 212 INDIA: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY END USER,
2018–2025 (USD MILLION) 176
8.5.4 ROAPAC 176
TABLE 213 ROAPAC: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY APPLICATION, 2018–2025 (USD MILLION) 176
TABLE 214 ROAPAC: BREAST CANCER TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 177
TABLE 215 ROAPAC: OSTEOPOROSIS TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 177
TABLE 216 ROAPAC: INFECTIOUS DISEASE TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 177
TABLE 217 ROAPAC: PREGNANCY & FERTILITY TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 178
TABLE 218 ROAPAC: ULTRASOUND TESTS MARKET, BY TYPE,
2018–2025 (USD MILLION) 178
TABLE 219 ROAPAC: STD TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 178
TABLE 220 ROAPAC: PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET,
BY TYPE, 2018–2025 (USD MILLION) 179
TABLE 221 ROAPAC: CERVICAL CANCER TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 179
TABLE 222 ROAPAC: OVC TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 179
TABLE 223 ROAPAC: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY END USER,
2018–2025 (USD MILLION) 180
8.6 LATIN AMERICA 180
8.6.1 AVAILABILITY OF ADVANCED CARE AND INCREASING AWARENESS PROGRAMS TO FUEL MARKET GROWTH 180
TABLE 224 LATIN AMERICA: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY APPLICATION, 2018–2025 (USD MILLION) 181
TABLE 225 LATIN AMERICA: BREAST CANCER TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 181
TABLE 226 LATIN AMERICA: OSTEOPOROSIS TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 182
TABLE 227 LATIN AMERICA: INFECTIOUS DISEASE TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 182
TABLE 228 LATIN AMERICA: PREGNANCY & FERTILITY TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 182
TABLE 229 LATIN AMERICA: ULTRASOUND TESTS MARKET, BY TYPE,
2018–2025 (USD MILLION) 183
TABLE 230 LATIN AMERICA: STD TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 183
TABLE 231 LATIN AMERICA: PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 183
TABLE 232 LATIN AMERICA: CERVICAL CANCER TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 184
TABLE 233 LATIN AMERICA: OVC TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 184
TABLE 234 LATIN AMERICA: WOMEN’S HEALTH DIAGNOSTICS MARKET, BY END USER, 2018–2025 (USD MILLION) 184
8.7 MIDDLE EAST & AFRICA 185
8.7.1 INCREASING INCIDENCE OF LIFESTYLE DISEASES TO AUGMENT MARKET GROWTH IN THE MIDDLE EAST & AFRICA 185
TABLE 235 MIDDLE EAST & AFRICA: WOMEN’S HEALTH DIAGNOSTICS MARKET,
BY APPLICATION, 2018–2025 (USD MILLION) 185
TABLE 236 MIDDLE EAST & AFRICA: BREAST CANCER TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 186
TABLE 237 MIDDLE EAST & AFRICA: OSTEOPOROSIS TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 186
TABLE 238 MIDDLE EAST & AFRICA: INFECTIOUS DISEASE TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 186
TABLE 239 MIDDLE EAST & AFRICA: PREGNANCY & FERTILITY TESTING MARKET,
BY TYPE, 2018–2025 (USD MILLION) 187
TABLE 240 MIDDLE EAST & AFRICA: ULTRASOUND TESTS MARKET, BY TYPE,
2018–2025 (USD MILLION) 187
TABLE 241 MIDDLE EAST & AFRICA: STD TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 187
TABLE 242 MIDDLE EAST & AFRICA: PRENATAL GENETIC SCREENING & CARRIER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 188
TABLE 243 MIDDLE EAST & AFRICA: CERVICAL CANCER TESTING MARKET, BY TYPE, 2018–2025 (USD MILLION) 188
TABLE 244 MIDDLE EAST & AFRICA: OVC TESTING MARKET, BY TYPE,
2018–2025 (USD MILLION) 188
TABLE 245 MIDDLE EAST & AFRICA: WOMEN’S HEALTH DIAGNOSTICS MARKET,
BY END USER, 2018–2025 (USD MILLION) 189

9 COMPETITIVE LANDSCAPE 190
9.1 OVERVIEW 190
FIGURE 20 KEY GROWTH STRATEGIES ADOPTED BY MARKET PLAYERS FROM JANUARY 2018 TO DECEMBER 2020 190
9.2 GEOGRAPHICAL ASSESSMENT OF THE MAJOR PLAYERS IN THE WOMEN’S HEALTH DIAGNOSTICS MARKET 191
FIGURE 21 GEOGRAPHIC REVENUE MIX: WOMEN’S HEALTH DIAGNOSTICS MARKET (2019) 191
9.3 REVENUE SHARE ANALYSIS OF TOP PLAYERS 191
FIGURE 22 TOP PLAYERS DOMINATE THE GLOBAL MARKET 192
9.4 MARKET SHARE ANALYSIS 192
FIGURE 23 WOMEN’S HEALTH DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2019 193
9.5 COMPETITIVE LEADERSHIP MAPPING 194
9.5.1 STARS 194
9.5.2 EMERGING LEADERS 194
9.5.3 PERVASIVE PLAYERS 195
9.5.4 EMERGING COMPANIES 195
FIGURE 24 WOMEN’S HEALTH DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING (2019) 196
9.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS 196
9.6.1 PROGRESSIVE COMPANIES 196
9.6.2 DYNAMIC COMPANIES 197
9.6.3 STARTING BLOCKS 197
9.6.4 RESPONSIVE COMPANIES 197
FIGURE 25 WOMEN’S HEALTH DIAGNOSTICS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS (2019) 198
9.7 COMPETITIVE SITUATION AND TRENDS 199
9.7.1 PRODUCT LAUNCHES & ENHANCEMENTS 199
9.7.2 EXPANSIONS 200
9.7.3 ACQUISITIONS 200
9.7.4 OTHER STRATEGIES 201
10 COMPANY PROFILES 202
(Business Overview, Products Offered, Recent Developments, MnM View)*
10.1 QUEST DIAGNOSTICS INCORPORATED 202
FIGURE 26 QUEST DIAGNOSTICS INCORPORATED: COMPANY SNAPSHOT (2019) 203
10.2 HOLOGIC, INC. 206
FIGURE 27 HOLOGIC, INC.: COMPANY SNAPSHOT (2020) 206
10.3 SIEMENS AG 210
FIGURE 28 SIEMENS AG: COMPANY SNAPSHOT (2020) 210
10.4 PERKINELMER, INC. 213
FIGURE 29 PERKINELMER, INC.: COMPANY SNAPSHOT (2019) 213
10.5 F. HOFFMANN-LA ROCHE LTD. 215
FIGURE 30 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2019) 215
10.6 CARDINAL HEALTH, INC. 217
FIGURE 31 CARDINAL HEALTH, INC.: COMPANY SNAPSHOT (2020) 217
10.7 GENERAL ELECTRIC COMPANY 219
FIGURE 32 GENERAL ELECTRIC COMPANY: COMPANY SNAPSHOT (2019) 219
10.8 BECTON, DICKINSON AND COMPANY 221
FIGURE 33 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2020) 221
10.9 ABBOTT LABORATORIES 223
FIGURE 34 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2019) 223
10.10 BIOMÉRIEUX SA 225
10.11 KONINKLIJKE PHILIPS N.V. 226
FIGURE 35 KONINKLIJKE PHILIPS N.V.: COMPANY SNAPSHOT (2019) 226
10.12 GUIDED THERAPEUTICS, INC. 228
10.13 SUPERSONIC IMAGINE 229
10.14 FUJIFILM HOLDINGS CORPORATION 230
10.15 DIALAB GMBH 231
10.16 CARESTREAM HEALTH, INC. 232
10.17 MEDGYN PRODUCTS, INC. 233
10.18 COOK MEDICAL, INC. 235
10.19 OSTEOMETER MEDITECH, INC. 236
10.20 NEUROLOGICA CORPORATION 237
*Business Overview, Products Offered, Recent Developments, MnM View might not be captured in case of unlisted companies.
11 APPENDIX 238
11.1 INSIGHTS FROM INDUSTRY EXPERTS 238
11.2 DISCUSSION GUIDE 239
11.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 243
11.4 AVAILABLE CUSTOMIZATIONS 245
11.5 RELATED REPORTS 245
11.6 AUTHOR DETAILS 246

★調査レポート[世界の女性向け健康診断市場予測:用途別、エンドユーザー別] ( Women’s Health Diagnostics Market by Application (Biopsy, Cervical & Ovarian Cancer Testing, PAP Smear, HPV, TORCH, Prenatal Testing, Hepatitis, Ultrasound, Obstetrics), End User (Hospitals, Clinics, Home Care), COVID-19 Impact – Global Forecast to 2025 / MD4774) 販売に関する免責事項
[世界の女性向け健康診断市場予測:用途別、エンドユーザー別] ( Women’s Health Diagnostics Market by Application (Biopsy, Cervical & Ovarian Cancer Testing, PAP Smear, HPV, TORCH, Prenatal Testing, Hepatitis, Ultrasound, Obstetrics), End User (Hospitals, Clinics, Home Care), COVID-19 Impact – Global Forecast to 2025 / MD4774) についてEメールでお問い合わせ


◆H&Iグローバルリサーチ株式会社のお客様(例)◆